A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes. The study will last approximately 47 weeks and may include about 12 visits.
Inclusion Criteria:
Exclusion Criteria:
Pittsburgh, Pennsylvania 15243, United States
CABA, AR-B C1425DES, Argentina
Ciudad Autonoma de Buenos Aire, AR-B C1119ACN, Argentina
C.a.b.a., AR-C C1205AAO, Argentina
CABA, Buenos Aires C1056ABJ, Argentina
CABA, Buenos Aires C1120AAC, Argentina
CABA, Buenos Aires C1425AGC, Argentina
Ciudad Autonoma de Buenos Air, Buenos Aires C1128AAF, Argentina
Mar del Plata, Buenos Aires (B7600FZN), Argentina
Ciudad Autonoma de Buenos Aire, C1204AAD, Argentina
São José dos Campos, Br-sp 12243-280, Brazil
Ramat Gan, Central District 5262100, Israel
Ciudad Madero, Tamaulipas 89440, Mexico